Bavarian Nordic A/S announced that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN®? smallpox vaccine to rescEU, a strategic reserve within the European Union (EU). This order follows an initial contract awarded in June 2023 and is also for delivery in 2024.

The vaccines will be stockpiled in another EU country thus expanding the EU's capability to respond to biological threats and emergencies in the future by enabling rapid deployment of medical countermeasures to its member states and other countries participating in the EU Civil Protection Mechanism.